48 results on '"Kristensen, Gunnar B"'
Search Results
2. DCE-MRI of locally-advanced carcinoma of the uterine cervix: Tofts analysis versus non-model-based analyses
- Author
-
Lund, Kjersti V., Simonsen, Trude G., Kristensen, Gunnar B., and Rofstad, Einar K.
- Published
- 2020
- Full Text
- View/download PDF
3. A national, prospective observational study of first recurrence after primary treatment for gynecological cancer in Norway
- Author
-
Vistad, Ingvild, Bjørge, Line, Solheim, Olesya, Fiane, Bent, Sachse, Kurt, Tjugum, Jostein, Skrøppa, Siri, Bentzen, Anne G., Stokstad, Trine, Iversen, Grete A., Salvesen, Helga B., Kristensen, Gunnar B., and Dørum, Anne
- Published
- 2017
- Full Text
- View/download PDF
4. CA-125 Early Dynamics to Predict Overall Survival in Women with Newly Diagnosed Advanced Ovarian Cancer Based on Meta-Analysis Data.
- Author
-
Karamouza, Eleni, Glasspool, Rosalind M., Kelly, Caroline, Lewsley, Liz-Anne, Carty, Karen, Kristensen, Gunnar B., Ethier, Josee-Lyne, Kagimura, Tatsuo, Yanaihara, Nozomu, Cecere, Sabrina Chiara, You, Benoit, Boere, Ingrid A., Pujade-Lauraine, Eric, Ray-Coquard, Isabelle, Proust-Lima, Cécile, and Paoletti, Xavier
- Subjects
THERAPEUTIC use of antineoplastic agents ,OVARIAN tumors ,PREDICTIVE tests ,META-analysis ,CONFIDENCE intervals ,SYSTEMATIC reviews ,CANCER chemotherapy ,EARLY detection of cancer ,COMPARATIVE studies ,RESEARCH funding ,TUMOR antigens ,TUMOR markers ,PREDICTION models ,RECEIVER operating characteristic curves ,WOMEN'S health ,OVERALL survival - Abstract
Simple Summary: Cancer antigen 125 (CA-125) is a protein found at a high concentration in the blood of patients with specific types of cancer, mainly ovarian cancer. In 2004, the Gynecologic Cancer Intergroup (GCIG) proposed criteria defining response to treatment, as well as disease progression, based on the CA-125 concentration. Ever since, for the follow-up of ovarian cancer patients, the CA-125 concentration and/or CT-scans are used. This paper aims to compare different summaries of CA-125 evolution in the 3 to 6 months following treatment initiation in newly diagnosed advanced ovarian cancer and explore their prognostic capacity to predict overall survival. Based on individual patient data from the GCIG meta-analysis, we propose the most appropriate timeframe between follow-up and the prediction horizon in order to obtain robust, dynamic, individual predictions. (1) Background: Cancer antigen 125 (CA-125) is a protein produced by ovarian cancer cells that is used for patients' monitoring. However, the best ways to analyze its decline and prognostic role are poorly quantified. (2) Methods: We leveraged individual patient data from the Gynecologic Cancer Intergroup (GCIG) meta-analysis (N = 5573) to compare different approaches summarizing the early trajectory of CA-125 before the prediction time (called the landmark time) at 3 or 6 months after treatment initiation in order to predict overall survival. These summaries included observed and estimated measures obtained by a linear mixed model (LMM). Their performances were evaluated by 10-fold cross-validation with the Brier score and the area under the ROC (AUC). (3) Results: The estimated value and the last observed value at 3 months were the best measures used to predict overall survival, with an AUC of 0.75 CI 95% [0.70; 0.80] at 24 and 36 months and 0.74 [0.69; 0.80] and 0.75 [0.69; 0.80] at 48 months, respectively, considering that CA-125 over 6 months did not improve the AUC, with 0.74 [0.68; 0.78] at 24 months and 0.71 [0.65; 0.76] at 36 and 48 months. (4) Conclusions: A 3-month surveillance provided reliable individual information on overall survival until 48 months for patients receiving first-line chemotherapy. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
5. miR-200a/b/-429 downregulation is a candidate biomarker of tumor radioresistance and independent of hypoxia in locally advanced cervical cancer.
- Author
-
Nilsen, Anja, Hillestad, Tiril, Skingen, Vilde E., Aarnes, Eva-Katrine, Fjeldbo, Christina S., Hompland, Tord, Sandø Evensen, Tina, Stokke, Trond, Kristensen, Gunnar B., Grallert, Beata, and Lyng, Heidi
- Published
- 2022
- Full Text
- View/download PDF
6. Prognostic significance of dysadherin expression in cervical squamous cell carcinoma
- Author
-
Wu, Dan, Qiao, Yuhuan, Kristensen, Gunnar B., Li, Shanshan, Troen, Gunhild, Holm, Ruth, Nesland, Jahn M., and Suo, Zhenhe
- Published
- 2004
- Full Text
- View/download PDF
7. Genomic imbalances in endometrial adenocarcinomas – Comparison of DNA ploidy, karyotyping and comparative genomic hybridization
- Author
-
Kildal, Wanja, Micci, Francesca, Risberg, Bjørn, Abeler, Vera M., Kristensen, Gunnar B., Heim, Sverre, and Danielsen, Håvard E.
- Published
- 2012
- Full Text
- View/download PDF
8. Re: New Guidelines to Evaluate the Response to Treatment in Solid Tumors [Ovarian Cancer]
- Author
-
Vergote, Ignace, Rustin, Gordon J. S., Eisenhauer, Elisabeth A., Kristensen, Gunnar B., Pujade-Lauraine, Eric, Parmar, Mahesh K. B., Friedlander, Michael, Jakobsen, Anders, and Vermorken, Jan B.
- Published
- 2000
9. A study of weekly Taxol® in patients with recurrent platinum resistant ovarian cancer.
- Author
-
Kaern, Janne, Tropé, Claes, Baekelandt, Mark, Kristensen, Gunnar B, and Gundersen, Glenn
- Published
- 2000
10. Metabolic mapping by use of high-resolution magic angle spinning 1H MR spectroscopy for assessment of apoptosis in cervical carcinomas
- Author
-
Sundfør Kolbein, Jensen Line R, Bathen Tone F, Sitter Beathe, Lyng Heidi, Kristensen Gunnar B, and Gribbestad Ingrid S
- Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Background High-resolution magic angle proton magnetic resonance spectroscopy (HR 1H MAS MRS) provides a broad metabolic mapping of intact tumor samples and allows for microscopy investigations of the samples after spectra acquisition. Experimental studies have suggested that the method can be used for detection of apoptosis, but this has not been investigated in a clinical setting so far. We have explored this hypothesis in cervical cancers by searching for metabolites associated with apoptosis that were not influenced by other histopathological parameters like tumor load and tumor cell density. Methods Biopsies (n = 44) taken before and during radiotherapy in 23 patients were subjected to HR MAS MRS. A standard pulse-acquire spectrum provided information about lipids, and a spin-echo spectrum enabled detection of non-lipid metabolites in the lipid region of the spectra. Apoptotic cell density, tumor cell fraction, and tumor cell density were determined by histopathological analysis after spectra acquisition. Results The apoptotic cell density correlated with the standard pulse-acquire spectra (p < 0.001), but not with the spin-echo spectra, showing that the lipid metabolites were most important. The combined information of all lipids contributed to the correlation, with a major contribution from the ratio of fatty acid -CH2 to CH3 (p = 0.02). In contrast, the spin-echo spectra contained the main information on tumor cell fraction and tumor cell density (p < 0.001), for which cholines, creatine, taurine, glucose, and lactate were most important. Significant correlations were found between tumor cell fraction and glucose concentration (p = 0.001) and between tumor cell density and glycerophosphocholine (GPC) concentration (p = 0.024) and ratio of GPC to choline (p < 0.001). Conclusion Our findings indicate that the apoptotic activity of cervical cancers can be assessed from the lipid metabolites in HR MAS MR spectra and that the HR MAS data may reveal novel information on the metabolic changes characteristic of apoptosis. These changes differed from those associated with tumor load and tumor cell density, suggesting an application of the method to explore the role of apoptosis in the course of the disease.
- Published
- 2007
- Full Text
- View/download PDF
11. Gene expressions and copy numbers associated with metastatic phenotypes of uterine cervical cancer
- Author
-
Sundfør Kolbein, Oksefjell Halldis, Knutstad Kjetil, Kaalhus Olav, Holm Ruth, Svendsrud Debbie H, Brøvig Runar S, Lyng Heidi, Kristensen Gunnar B, and Stokke Trond
- Subjects
Biotechnology ,TP248.13-248.65 ,Genetics ,QH426-470 - Abstract
Abstract Background A better understanding of the development of metastatic disease and the identification of molecular markers for cancer spread would be useful for the design of improved treatment strategies. This study was conducted to identify gene expressions associated with metastatic phenotypes of locally advanced cervical carcinomas and investigate whether gains or losses of these genes could play a role in regulation of the transcripts. Gene expressions and copy number changes were determined in primary tumors from 29 patients with and 19 without diagnosed lymph node metastases by use of cDNA and genomic microarray techniques, respectively. Results Thirty-one genes that differed in expression between the node positive and negative tumors were identified. Expressions of eight of these genes (MRPL11, CKS2, PDK2, MRPS23, MSN, TBX3, KLF3, LSM3) correlated with progression free survival in univariate analysis and were therefore more strongly associated with metastatic phenotypes than the others. Immunohistochemistry data of CKS2 and MSN showed similar relationships to survival. The prognostic genes clustered into two groups, suggesting two major metastatic phenotypes. One group was associated with rapid proliferation, oxidative phosphorylation, invasiveness, and tumor size (MRPS23, MRPL11, CKS2, LSM3, TBX3, MSN) and another with hypoxia tolerance, anaerobic metabolism, and high lactate content (PDK2, KLF3). Multivariate analysis identified tumor volume and PDK2 expression as independent prognostic variables. Gene copy number changes of the differentially expressed genes were not frequent, but correlated with the expression level for seven genes, including MRPS23, MSN, and LSM3. Conclusion Gene expressions associated with known metastatic phenotypes of cervical cancers were identified. Our findings may indicate molecular mechanisms underlying development of these phenotypes and be useful as markers of cancer spread. Gains or losses of the genes may be involved in development of the metastatic phenotypes in some cases, but other mechanisms for transcriptional regulation are probably important in the majority of tumors.
- Published
- 2006
- Full Text
- View/download PDF
12. Variation in gene expression patterns in effusions and primary tumors from serous ovarian cancer patients
- Author
-
Tropè Claes G, Givant-Horwitz Vered, Goldberg Iris, Berner Aasmund, Risberg Björn, Flørenes Vivi, Reich Reuven, Skrede Martina, Davidson Ben, Schaner Marci E, Kristensen Gunnar B, Nesland Jahn M, and Børresen-Dale Anne-Lise
- Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Background While numerous studies have characterized primary ovarian tumors, little information is available regarding expression patterns of metastatic sites of this cancer. To define sets of genes that distinguish primary and metastatic ovarian tumors, we used cDNA microarrays to characterize global gene expression patterns in 38 effusions (28 peritoneal, 10 pleural) and 8 corresponding primary ovarian tumors, and searched for associations between expression patterns and clinical parameters. Results We observed multidimensional variation in expression patterns among the cancers. Coordinate variation in expression of genes from two chromosomal regions, 8q and 19q, was seen in subsets of the cancers indicating possible amplifications in these regions. A set of 112 unique genes of known function was differentially expressed between primary tumors and effusions using supervised analysis. Relatively few differences were seen between effusions isolated from the pleural and peritoneal cavities or between effusions from patients diagnosed with stage III and stage IV cancers. A set of 84 unique genes was identified that distinguished high from lower grade ovarian cancers. The results were corroborated using immunocytochemistry, mRNA in situ hybridization, and immunoblotting. Conclusion The extensive variation in expression patterns observed underscores the molecular heterogeneity of ovarian cancer, but suggests a similar molecular profile for ovarian carcinoma cells in serosal cavities.
- Published
- 2005
- Full Text
- View/download PDF
13. Gene Expression Programs in Response to Hypoxia: Cell Type Specificity and Prognostic Significance in Human Cancers
- Author
-
Chi, Jen-Tsan, Wang, Zhen, Nuyten, Dimitry S. A, Rodriguez, Edwin H, Schaner, Marci E, Salim, Ali, Wang, Yun, Kristensen, Gunnar B, Helland, Åslaug, Børresen-Dale, Anne-Lise, Giaccia, Amato, Longaker, Michael T, Hastie, Trevor, Yang, George P, van de Vijver, Marc J, and Brown, Patrick O
- Subjects
Cancer: gynecological ,Renal Medicine ,Oncology ,Nephrology ,Pharmacology/Drug Discovery ,Systems Biology ,Genetics ,Cell Biology ,Genetics/Genomics/Gene Therapy ,Molecular Biology/Structural Biology ,Research Article ,Cancer Biology - Abstract
Background Inadequate oxygen (hypoxia) triggers a multifaceted cellular response that has important roles in normal physiology and in many human diseases. A transcription factor, hypoxia-inducible factor (HIF), plays a central role in the hypoxia response; its activity is regulated by the oxygen-dependent degradation of the HIF-1α protein. Despite the ubiquity and importance of hypoxia responses, little is known about the variation in the global transcriptional response to hypoxia among different cell types or how this variation might relate to tissue- and cell-specific diseases. Methods and Findings We analyzed the temporal changes in global transcript levels in response to hypoxia in primary renal proximal tubule epithelial cells, breast epithelial cells, smooth muscle cells, and endothelial cells with DNA microarrays. The extent of the transcriptional response to hypoxia was greatest in the renal tubule cells. This heightened response was associated with a uniquely high level of HIF-1α RNA in renal cells, and it could be diminished by reducing HIF-1α expression via RNA interference. A gene-expression signature of the hypoxia response, derived from our studies of cultured mammary and renal tubular epithelial cells, showed coordinated variation in several human cancers, and was a strong predictor of clinical outcomes in breast and ovarian cancers. In an analysis of a large, published gene-expression dataset from breast cancers, we found that the prognostic information in the hypoxia signature was virtually independent of that provided by the previously reported wound signature and more predictive of outcomes than any of the clinical parameters in current use. Conclusions The transcriptional response to hypoxia varies among human cells. Some of this variation is traceable to variation in expression of the HIF1A gene. A gene-expression signature of the cellular response to hypoxia is associated with a significantly poorer prognosis in breast and ovarian cancer., The transcriptional response to hypoxia varies between cell types. A gene-expression signature of the cellular response to hypoxia is associated with a significantly poorer prognosis in breast and ovarian cancer.
- Published
- 2006
14. Systematic analysis of circulating soluble angiogenesis-associated proteins in ICON7 identifies Tie2 as a biomarker of vascular progression on bevacizumab.
- Author
-
Zhou, Cong, Clamp, Andrew, Backen, Alison, Berzuini, Carlo, Renehan, Andrew, Banks, Rosamonde E, Kaplan, Richard, Scherer, Stefan J, Kristensen, Gunnar B, Pujade-Lauraine, Eric, Dive, Caroline, and Jayson, Gordon C
- Abstract
Background: There is a critical need for predictive/resistance biomarkers for VEGF inhibitors to optimise their use.Methods: Blood samples were collected during and following treatment and, where appropriate, upon progression from ovarian cancer patients in ICON7, a randomised phase III trial of carboplatin and paclitaxel with or without bevacizumab. Plasma concentrations of 15 circulating angio-biomarkers were measured using a validated multiplex ELISA, analysed through a novel network analysis and their relevance to the PFS then determined.Results: Samples (n=650) were analysed from 92 patients. Bevacizumab induced correlative relationships between Ang1 and Tie2 plasma concentrations, which reduced after initiation of treatment and remained decreased until progressive disease occurred. A 50% increase from the nadir in the concentration of circulating Tie2 (or the product of circulating Ang1 and Tie2) predicted tumour progression. Combining Tie2 with GCIG-defined Ca125 data yielded a significant improvement in the prediction of progressive disease in patients receiving bevacizumab in comparison with Ca125 alone (74.1% vs 47.3%, P<1 × 10(-9)).Conclusions: Tie2 is a vascular progression marker for bevacizumab-treated ovarian cancer patients. Tie2 in combination with Ca125 provides superior information to clinicians on progressive disease in patients with VEGFi-treated ovarian cancers. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
15. Identification and Validation of Reference Genes for RT-qPCR Studies of Hypoxia in Squamous Cervical Cancer Patients.
- Author
-
Fjeldbo, Christina S., Aarnes, Eva-Katrine, Malinen, Eirik, Kristensen, Gunnar B., and Lyng, Heidi
- Subjects
CERVICAL cancer diagnosis ,CERVICAL cancer ,SQUAMOUS cell carcinoma ,GENE expression ,BIOMARKERS ,REVERSE transcriptase polymerase chain reaction ,HYPOXEMIA ,GENETICS - Abstract
Hypoxia is an adverse factor in cervical cancer, and hypoxia-related gene expression could be a powerful biomarker for identifying the aggressive hypoxic tumors. Reverse transcription quantitative PCR (RT-qPCR) is a valuable method for gene expression studies, but suitable reference genes for data normalization that are independent of hypoxia status and clinical parameters of cervical tumors are lacking. In the present work, we aimed to identify reference genes for RT-qPCR studies of hypoxia in squamous cervical cancer. From 422 candidate reference genes selected from the literature, we used Illumina array-based expression profiles to identify 182 genes not affected by hypoxia in cervical cancer, i.e. genes regulated by hypoxia in eight cervical cancer cell lines or correlating with the hypoxia-associated dynamic contrast-enhanced magnetic resonance imaging parameter A
Brix in 42 patients, were excluded. Among the 182 genes, nine candidates (CHCHD1, GNB2L1, IPO8, LASP1, RPL27A, RPS12, SOD1, SRSF9, TMBIM6) that were not associated with tumor volume, stage, lymph node involvement or disease progression in array data of 150 patients, were selected for further testing by RT-qPCR. geNorm and NormFinder analyses of RT-qPCR data of 74 patients identified CHCHD1, SRSF9 and TMBIM6 as the optimal set of reference genes, with stable expression both overall and across patient subgroups with different hypoxia status (ABrix ) and clinical parameters. The suitability of the three reference genes were validated in studies of the hypoxia-induced genes DDIT3, ERO1A, and STC2. After normalization, the RT-qPCR data of these genes showed a significant correlation with Illumina expression (P<0.001, n = 74) and ABrix (P<0.05, n = 32), and the STC2 data were associated with clinical outcome, in accordance with the Illumina data. Thus, CHCHD1, SRSF9 and TMBIM6 seem to be suitable reference genes for studying hypoxia-related gene expression in squamous cervical cancer samples by RT-qPCR. Moreover, STC2 is a promising prognostic hypoxia biomarker in cervical cancer. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
16. Interplay between promoter methylation and chromosomal loss in gene silencing at 3p11-p14 in cervical cancer.
- Author
-
Lando, Malin, Fjeldbo, Christina S, Wilting, Saskia M, C Snoek, Barbara, Aarnes, Eva-Katrine, Forsberg, Malin F, Kristensen, Gunnar B, Steenbergen, Renske DM, and Lyng, Heidi
- Published
- 2015
- Full Text
- View/download PDF
17. Examestane in advanced or recurrent endometrial carcinoma: a prospective phase II study by the Nordic Society of Gynecologic Oncology (NSGO).
- Author
-
Lindemann, Kristina, Malander, Susanne, Christensen, Rene D., Mirza, Mansoor R., Kristensen, Gunnar B., Aavall-Lundqvist, Elisabeth, Vergote, Ignace, Rosenberg, Per, Boman, Karin, and Nordstrøm, Britta
- Subjects
ENDOMETRIAL cancer ,CANCER relapse ,AROMATASE inhibitors ,DRUG efficacy ,MEDICATION safety ,LONGITUDINAL method ,ESTROGEN receptors ,CANCER invasiveness ,PATIENTS ,THERAPEUTICS - Abstract
Background We evaluated the efficacy and safety of the aromatase inhibitor exemestane in patients with advanced, persistent or recurrent endometrial carcinoma. Methods We performed an open-label one-arm, two-stage, phase II study of 25 mg of oral exemestane in 51 patients with advanced (FIGO stage III-IV) or relapsed endometrioid endometrial cancer. Patients were stratified into subsets of estrogen receptor (ER) positive and ER negative patients. Results Recruitment to the ER negative group was stopped prematurely after 12 patients due to slow accrual. In the ER positive patients, we observed an overall response rate of 10%, and a lack of progression after 6 months in 35% of the patients. No responses were registered in the ER negative patients, and all had progressive disease within 6 months. For the total group of patients, the median progression free survival (PFS) was 3.1 months (95% CI: 2.0-4.1). In the ER positive patients the median PFS was 3.8 months (95% CI: 0.7-6.9) and in the ER negative patients it was 2.6 months (95% CI: 2.1-3-1). In the ER positive patients the median overall survival (OS) time was 13.3 months (95% CI: 7.7-18.9), in the ER negative patients the corresponding numbers were 6.1 months (95% CI: 4.1-8.2). Treatment with exemestane was well tolerated. Conclusion Treatment of estrogen positive advanced or recurrent endometrial cancer with exemestane, an aromatase inhibitor, resulted in a response rate of 10% and lack of progression after 6 months in 35% of the patients. Trial registration Trial identification number (Clinical Trials.gov): NCT01965080. Nordic Society of Gynecological Oncology: NSGO-EC-0302. EudraCT number: 2004-001103-35. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
18. Risk Stratification of Endometrial Cancer Patients: FIGO Stage, Biomarkers and Molecular Classification.
- Author
-
Kasius, Jenneke C., Pijnenborg, Johanna M. A., Lindemann, Kristina, Forsse, David, van Zwol, Judith, Kristensen, Gunnar B., Krakstad, Camilla, Werner, Henrica M. J., and Amant, Frédéric
- Subjects
LYMPH node surgery ,BIOPSY ,METASTASIS ,CANCER relapse ,RISK assessment ,CANCER patients ,TUMOR classification ,PERITONEUM ,ENDOMETRIAL tumors ,TUMOR markers ,CYTOLOGY - Abstract
Simple Summary: Endometrial cancer (EC) is the most common gynaecologic malignancy in developed countries. Most patients are sufficiently treated with removal of uterus, tubes and ovaries. It depends on the estimated risk of metastases at diagnosis if more extensive surgery (removal of lymph nodes, peritoneum and/or omentum), to detect small metastases, is indicated. Metastases are associated with a higher risk of recurrence and justify adjuvant treatment (i.e., radiotherapy and/or chemotherapy). Recently it is advised to also subdivide EC into four molecular subgroups. Each subgroup is highly associated to a certain risk of recurrence and helps to decide for adjuvant treatment. What surgery should be performed in each of the subgroups is currently unknown. Moreover, it is uncertain if integration of other factors into the molecular classification could help to improve the risk classification. This review summarizes different aspects of surgery. Moreover, the relation between metastases and other factors including molecular classification are evaluated. Endometrial cancer (EC) is the most common gynaecologic malignancy in developed countries. The main challenge in EC management is to correctly estimate the risk of metastases at diagnosis and the risk to develop recurrences in the future. Risk stratification determines the need for surgical staging and adjuvant treatment. Detection of occult, microscopic metastases upstages patients, provides important prognostic information and guides adjuvant treatment. The molecular classification subdivides EC into four prognostic subgroups: POLE ultramutated; mismatch repair deficient (MMRd); nonspecific molecular profile (NSMP); and TP53 mutated (p53abn). How surgical staging should be adjusted based on preoperative molecular profiling is currently unknown. Moreover, little is known whether and how other known prognostic biomarkers affect prognosis prediction independent of or in addition to these molecular subgroups. This review summarizes the factors incorporated in surgical staging (i.e., peritoneal washing, lymph node dissection, omentectomy and peritoneal biopsies), and its impact on prognosis and adjuvant treatment decisions in an era of molecular classification of EC. Moreover, the relation between FIGO stage and molecular classification is evaluated including the current gaps in knowledge and future perspectives. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
19. High Levels of Genomic Aberrations in Serous Ovarian Cancers Are Associated with Better Survival.
- Author
-
Baumbusch, Lars O., Helland, Åslaug, Yun Wang, Liestøl, Knut, Schaner, Marci E., Holm, Ruth, Etemadmoghadam, Dariush, Alsop, Kathryn, Brown, Pat, Fereday, Sian, DeFazio, Anna, Bowtell, David D. L., Kristensen, Gunnar B., Lingjærde, Ole Christian, Børresen-Dale, Anne-Lise, and Mitchell, Gillian
- Subjects
OVARIAN cancer ,HUMAN genome ,CANCER genetics ,MEDICAL genetics - Abstract
Genomic instability and copy number alterations in cancer are generally associated with poor prognosis; however, recent studies have suggested that extreme levels of genomic aberrations may be beneficial for the survival outcome for patients with specific tumour types. We investigated the extent of genomic instability in predominantly high-grade serous ovarian cancers (SOC) using two independent datasets, generated in Norway (n = 74) and Australia (n = 70), respectively. Genomic instability was quantified by the Total Aberration Index (TAI), a measure of the abundance and genomic size of copy number changes in a tumour. In the Norwegian cohort, patients with TAI above the median revealed significantly prolonged overall survival (p<0.001) and progression-free survival (p<0.05). In the Australian cohort, patients with above median TAI showed prolonged overall survival (p<0.05) and moderately, but not significantly, prolonged progression-free survival. Results were confirmed by univariate and multivariate Cox regression analyses with TAI as a continuous variable. Our results provide further evidence supporting an association between high level of genomic instability and prolonged survival of high-grade SOC patients, possibly as disturbed genome integrity may lead to increased sensitivity to chemotherapeutic agents. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
20. The prognostic value of adaptive nuclear texture features from patient gray level entropy matrices in early stage ovarian cancer.
- Author
-
Nielsen, Birgitte, Albregtsen, Fritz, Kildal, Wanja, Abeler, Vera M., Kristensen, Gunnar B., and Danielsen, Håvard E.
- Subjects
TEXTURE analysis (Image processing) ,ENTROPY ,OVARIAN cancer ,SPATIAL arrangement ,KAPLAN-Meier estimator ,MULTIVARIATE analysis ,PROGNOSIS - Abstract
Background: Nuclear texture analysis gives information about the spatial arrangement of the pixel gray levels in a digitized microscopic nuclear image, providing texture features that may be used as quantitative tools for prognosis of human cancer. The aim of the study was to evaluate the prognostic value of adaptive nuclear texture features in early stage ovarian cancer. Methods: 246 cases of early stage ovarian cancer were included in the analysis. Isolated nuclei (monolayers) were prepared from 50 μm tissue sections and stained with Feulgen-Schiff. Local gray level entropy was measured within small windows of each nuclear image and stored in gray level entropy matrices. A compact set of adaptive features was computed from these matrices. Results: Univariate Kaplan-Meier analysis showed significantly better relapse-free survival (p < 0.001) for patients with low adaptive feature values compared to patients with high adaptive feature values. The 10-year relapse-free survival was about 78% for patients with low feature values and about 52% for patients with high feature values. Adaptive features were found to be of independent prognostic significance for relapse-free survival in a multivariate analysis. Conclusion: Adaptive nuclear texture features from entropy matrices contain prognostic information and are of independent prognostic significance for relapse-free survival in early stage ovarian cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
21. Deregulation of MYCN, LIN28B and LET7 in a Molecular Subtype of Aggressive High-Grade Serous Ovarian Cancers.
- Author
-
Helland, Åslaug, Anglesio, Michael S., George, Joshy, Cowin, Prue A., Johnstone, Cameron N., House, Colin M., Sheppard, Karen E., Etemadmoghadam, Dariush, Melnyk, Nataliya, Rustgi, Anil K., Phillips, Wayne A., Johnsen, Hilde, Holm, Ruth, Kristensen, Gunnar B., Birrer, Michael J., Pearson, Richard B., Børresen-Dale, Anne-Lise, Huntsman, David G., deFazio, Anna, and Creighton, Chad J.
- Subjects
OVARIAN cancer diagnosis ,TUMOR diagnosis ,CANCER cells ,CANCER patients ,GENE frequency ,CANCER invasiveness ,CANCER cell growth ,DIAGNOSIS - Abstract
Molecular subtypes of serous ovarian cancer have been recently described. Using data from independent datasets including over 900 primary tumour samples, we show that deregulation of the Let-7 pathway is specifically associated with the C5 molecular subtype of serous ovarian cancer. DNA copy number and gene expression of HMGA2, alleles of Let-7, LIN28, LIN28B, MYC, MYCN, DICER1, and RNASEN were measured using microarray and quantitative reverse transcriptase PCR. Immunohistochemistry was performed on 127 samples using tissue microarrays and anti-HMGA2 antibodies. Fluorescence in situ hybridisation of bacterial artificial chromosomes hybridized to 239 ovarian tumours was used to measure translocation at the LIN28B locus. Short interfering RNA knockdown in ovarian cell lines was used to test the functionality of associations observed. Four molecular subtypes (C1, C2, C4, C5) of high-grade serous ovarian cancers were robustly represented in each dataset and showed similar pattern of patient survival. We found highly specific activation of a pathway involving MYCN, LIN28B, Let-7 and HMGA2 in the C5 molecular subtype defined by MYCN amplification and over-expression, over-expression of MYCN targets including the Let-7 repressor LIN28B, loss of Let-7 expression and HMGA2 amplification and over-expression. DICER1, a known Let-7 target, and RNASEN were over-expressed in C5 tumours. We saw no evidence of translocation at the LIN28B locus in C5 tumours. The reported interaction between LIN28B and Let-7 was recapitulated by siRNA knockdown in ovarian cancer cell lines. Our results associate deregulation of MYCN and downstream targets, including Let-7 and oncofetal genes, with serous ovarian cancer. We define for the first time how elements of an oncogenic pathway, involving multiple genes that contribute to stem cell renewal, is specifically altered in a molecular subtype of serous ovarian cancer. By defining the drivers of a molecular subtype of serous ovarian cancers we provide a novel strategy for targeted therapeutic intervention. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
22. Gene Dosage, Expression, and Ontology Analysis Identifies Driver Genes in the Carcinogenesis and Chemoradioresistance of Cervical Cancer.
- Author
-
Lando, Malin, Holden, Marit, Bergersen, Linn C., Svendsrud, Debbie H., Stokke, Trond, Sundfør, Kolbein, Glad, Ingrid K., Kristensen, Gunnar B., and Lyng, Heidi
- Subjects
CERVICAL cancer ,GENE expression ,ONTOLOGY ,CARCINOGENESIS ,GENETIC regulation ,GENETIC research - Abstract
Integrative analysis of gene dosage, expression, and ontology (GO) data was performed to discover driver genes in the carcinogenesis and chemoradioresistance of cervical cancers. Gene dosage and expression profiles of 102 locally advanced cervical cancers were generated by microarray techniques. Fifty-two of these patients were also analyzed with the Illumina expression method to confirm the gene expression results. An independent cohort of 41 patients was used for validation of gene expressions associated with clinical outcome. Statistical analysis identified 29 recurrent gains and losses and 3 losses (on 3p, 13q, 21q) associated with poor outcome after chemoradiotherapy. The intratumor heterogeneity, assessed from the gene dosage profiles, was low for these alterations, showing that they had emerged prior to many other alterations and probably were early events in carcinogenesis. Integration of the alterations with gene expression and GO data identified genes that were regulated by the alterations and revealed five biological processes that were significantly overrepresented among the affected genes: apoptosis, metabolism, macromolecule localization, translation, and transcription. Four genes on 3p (RYBP, GBE1) and 13q (FAM48A, MED4) correlated with outcome at both the gene dosage and expression level and were satisfactorily validated in the independent cohort. These integrated analyses yielded 57 candidate drivers of 24 genetic events, including novel loci responsible for chemoradioresistance. Further mapping of the connections among genetic events, drivers, and biological processes suggested that each individual event stimulates specific processes in carcinogenesis through the coordinated control of multiple genes. The present results may provide novel therapeutic opportunities of both early and advanced stage cervical cancers. [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF
23. Metabolic mapping by use of high-resolution magic angle spinning 1H MR spectroscopy for assessment of apoptosis in cervical carcinomas.
- Author
-
Heidi Lyng, Sitter, Beathe, Bathen, Tone F., Jensen, Line R., Sundfør, Kolbein, Kristensen, Gunnar B., and Gribbestad, Ingrid S.
- Subjects
CERVICAL cancer ,APOPTOSIS ,SPECTRUM analysis ,CANCER in women ,ONCOLOGY - Abstract
Background: High-resolution magic angle proton magnetic resonance spectroscopy (HR 1H MAS MRS) provides a broad metabolic mapping of intact tumor samples and allows for microscopy investigations of the samples after spectra acquisition. Experimental studies have suggested that the method can be used for detection of apoptosis, but this has not been investigated in a clinical setting so far. We have explored this hypothesis in cervical cancers by searching for metabolites associated with apoptosis that were not influenced by other histopathological parameters like tumor load and tumor cell density. Methods: Biopsies (n = 44) taken before and during radiotherapy in 23 patients were subjected to HR MAS MRS. A standard pulse-acquire spectrum provided information about lipids, and a spin-echo spectrum enabled detection of non-lipid metabolites in the lipid region of the spectra. Apoptotic cell density, tumor cell fraction, and tumor cell density were determined by histopathological analysis after spectra acquisition. Results: The apoptotic cell density correlated with the standard pulse-acquire spectra (p <0.001), but not with the spin-echo spectra, showing that the lipid metabolites were most important. The combined information of all lipids contributed to the correlation, with a major contribution from the ratio of fatty acid -CH
2 to CH3 (p =0.02). In contrast, the spin-echo spectra contained the main information on tumor cell fraction and tumor cell density (p < 0.001), for which cholines, creatine, taurine, glucose, and lactate were most important. Significant correlations were found between tumor cell fraction and glucose concentration (p = 0.001) and between tumor cell density and glycerophosphocholine (GPC) concentration (p = 0.024) and ratio of GPC to choline (p < 0.001). Conclusion: Our findings indicate that the apoptotic activity of cervical cancers can be assessed from the lipid metabolites in HR MAS MR spectra and that the HR MAS data may reveal novel information on the metabolic changes characteristic of apoptosis. These changes differed from those associated with tumor load and tumor cell density, suggesting an application of the method to explore the role of apoptosis in the course of the disease. [ABSTRACT FROM AUTHOR]- Published
- 2007
- Full Text
- View/download PDF
24. Gene expressions and copy numbers associated with metastatic phenotypes of uterine cervical cancer.
- Author
-
Lyng, Heidi, Brovig, Runar S, Svendsrud, Debbie H, Holm, Ruth, Kaalhus, Olav, Knutstad, Kjetil, Oksefjell, Halldis, Sundfor, Kolbein, Kristensen, Gunnar B, and Stokke, Trond
- Subjects
GENE expression ,CERVICAL cancer ,UTERINE cancer ,BIOMARKERS ,METASTASIS ,GENES ,TUMORS - Abstract
Background: A better understanding of the development of metastatic disease and the identification of molecular markers for cancer spread would be useful for the design of improved treatment strategies. This study was conducted to identify gene expressions associated with metastatic phenotypes of locally advanced cervical carcinomas and investigate whether gains or losses of these genes could play a role in regulation of the transcripts. Gene expressions and copy number changes were determined in primary tumors from 29 patients with and 19 without diagnosed lymph node metastases by use of cDNA and genomic microarray techniques, respectively. Results: Thirty-one genes that differed in expression between the node positive and negative tumors were identified. Expressions of eight of these genes (MRPL11, CKS2, PDK2, MRPS23, MSN, TBX3, KLF3, LSM3) correlated with progression free survival in univariate analysis and were therefore more strongly associated with metastatic phenotypes than the others. Immunohistochemistry data of CKS2 and MSN showed similar relationships to survival. The prognostic genes clustered into two groups, suggesting two major metastatic phenotypes. One group was associated with rapid proliferation, oxidative phosphorylation, invasiveness, and tumor size (MRPS23, MRPL11, CKS2, LSM3, TBX3, MSN) and another with hypoxia tolerance, anaerobic metabolism, and high lactate content (PDK2, KLF3). Multivariate analysis identified tumor volume and PDK2 expression as independent prognostic variables. Gene copy number changes of the differentially expressed genes were not frequent, but correlated with the expression level for seven genes, including MRPS23, MSN, and LSM3. Conclusion: Gene expressions associated with known metastatic phenotypes of cervical cancers were identified. Our findings may indicate molecular mechanisms underlying development of these phenotypes and be useful as markers of cancer spread. Gains or losses of the genes may be involved in development of the metastatic phenotypes in some cases, but other mechanisms for transcriptional regulation are probably important in the majority of tumors. [ABSTRACT FROM AUTHOR]
- Published
- 2006
- Full Text
- View/download PDF
25. High sensitivity assays for docetaxel and paclitaxel in plasma using solid-phase extraction and high-performance liquid chromatography with UV detection.
- Author
-
Andersen, Anders, Warren, David J., Brunsvig, Paal F., Aamdal, Steinar, Kristensen, Gunnar B., and Olsen, Harald
- Subjects
CANCER treatment ,DOCETAXEL ,PACLITAXEL ,LIQUID chromatography ,SOLID phase extraction - Abstract
Background: The taxanes paclitaxel and docetaxel have traditionally been used in high doses every third week in the treatment of cancer. Lately there has been a trend towards giving weekly low doses to improve the therapeutic index. This article describes the development of high performance liquid chromatographic (HPLC) methods suitable for monitoring taxane levels in patients, focusing on patients receiving low-dose therapy. Methods: Paclitaxel and docetaxel were extracted from human plasma by solid phase extraction, and detected by absorbance at 227 nm after separation by reversed phase high performance liquid chromatography. The methods were validated and their performance were tested using samples from patients receiving paclitaxel or docetaxel. Results: The limits of quantitation were 1 nM for docetaxel and 1.2 nM for paclitaxel. For both compounds linearity was confirmed from the limit of quantitation up to 1000 nM in plasma. The recoveries ranged between 92% and 118% for docetaxel and between 76% and 104% for paclitaxel. Accuracy and precision were within international acceptance criteria, that is within ± 15%, except at the limit of quantitation where values within ± 20% are acceptable. Low-dose patients included in an on going clinical trial had a median docetaxel concentration of 2.8 nM at 72 hours post infusion. Patients receiving 100 mg/m
2 of paclitaxel had a mean paclitaxel concentration of 21 nM 48 hours after the end of infusion. Conclusion: We have developed an HPLC method using UV detection capable of quantifying 1 nM of docetaxel in plasma samples. The method should be useful for pharmacokinetic determinations at all relevant doses of docetaxel. Using a similar methodology paclitaxel can be quantified down to a concentration of 1.2 nM in plasma with acceptable accuracy and precision. We further demonstrate that the previously reported negative influence of Cremophor EL on assay performance may be overcome by degradation of the detergent by incubation with lipase. [ABSTRACT FROM AUTHOR]- Published
- 2006
- Full Text
- View/download PDF
26. Variation in gene expression patterns in effusions and primary tumors from serous ovarian cancer patients.
- Author
-
Schaner, Marci E., Davidson, Ben, Skrede, Martina, Reich, Reuven, Florenes, Vivi Ann, Risberg, Bjorn, Berner, Aasmund, Goldberg, Iris, Givant-Horwitz, Vered, Trope, Claes G., Kristensen, Gunnar B., Nesland, Jahn M., and Borresen-Dale, Anne-Lise
- Subjects
OVARIAN tumors ,GENE expression ,GENES ,IMMUNOCYTOCHEMISTRY ,EXUDATES & transudates - Abstract
Background: While numerous studies have characterized primary ovarian tumors, little information is available regarding expression patterns of metastatic sites of this cancer. To define sets of genes that distinguish primary and metastatic ovarian tumors, we used cDNA microarrays to characterize global gene expression patterns in 38 effusions (28 peritoneal, 10 pleural) and 8 corresponding primary ovarian tumors, and searched for associations between expression patterns and clinical parameters. Results: We observed multidimensional variation in expression patterns among the cancers. Coordinate variation in expression of genes from two chromosomal regions, 8q and 19q, was seen in subsets of the cancers indicating possible amplifications in these regions. A set of 112 unique genes of known function was differentially expressed between primary tumors and effusions using supervised analysis. Relatively few differences were seen between effusions isolated from the pleural and peritoneal cavities or between effusions from patients diagnosed with stage III and stage IV cancers. A set of 84 unique genes was identified that distinguished high from lower grade ovarian cancers. The results were corroborated using immunocytochemistry, mRNA in situ hybridization, and immunoblotting. Conclusion: The extensive variation in expression patterns observed underscores the molecular heterogeneity of ovarian cancer, but suggests a similar molecular profile for ovarian carcinoma cells in serosal cavities. [ABSTRACT FROM AUTHOR]
- Published
- 2005
- Full Text
- View/download PDF
27. Effect of the codon 72 polymorphism (c.215G>C, p.Arg72Pro) in combination with somatic sequence variants in the TP53 gene on survival in patients with advanced ovarian carcinoma.
- Author
-
Wang, Yun, Kringen, Pedro, Kristensen, Gunnar B., Holm, Ruth, Baekelandt, Mark M.O., Olivier, Magali, Skomedal, Hanne, Hainaut, Pierre, Tropé, Claes G., Abeler, Vera M., Nesland, Jahn M., Børresen-Dale, Anne-Lise, and Helland, Åslaug
- Abstract
This study was conducted to evaluate the frequency and prognostic impact of TP53 alterations stratified for the TP53 codon 72 polymorphism (c.215G>C, p.Arg72Pro) in a cohort of 109 patients with advanced ovarian carcinomas. TP53 sequence variants were observed in 80 of the 109 (73.4%) tumors and were significantly associated with grade of differentiation (P=0.001). A tendency towards higher frequency of sequence variants in tumors with higher FIGO stages was seen (P=0.05). The type of TP53 sequence variant (transition A:T>G:C vs. G:C>A:T at CpG dinucleotides, and transversion G:C>T:A) had significant correlation with patients' age (P=0.04) with more A:T>G:C in patients over 60 years old. No significant associations were found between frequency of sequence variants and age at diagnosis, histological type, size of residual tumor after primary surgery, or long-term survival. Analyses of the codon 72 polymorphism in tumor DNA gave a higher frequency of homozygosity/hemizygosity than expected from the population frequency, particularly for the Pro allele. Tumors homozygous or hemizygous for the Pro allele had significantly higher frequency of TP53 sequence variants, particularly of the nonmissense type (P=0.002), and patients with these types of alterations had significantly shorter survival (P=0.04). TP53 protein accumulation, determined by immunohistochemistry (IHC), was found in 67.9% (74 out of 109) of the tumors, was significantly more common among serous than nonserous ovarian carcinomas (P=0.008), and had a significant effect on progression-free survival (P=0.03). p63 (TP73L; formerly TP63) and p73 (TP73) protein accumulation detected by IHC was seen in 67.9 and 0% of the tumors, respectively. A significantly higher frequency of p63-positive cases was seen among serous tumors (P=0.008) and tended to increase with increasing FIGO stages (P=0.05), but had no significant effect on survival. No association between p63 protein accumulation and TP53 protein accumulation was seen. Hum Mutat 24:21-34, 2004. © 2004 Wiley-Liss, Inc. [ABSTRACT FROM AUTHOR]
- Published
- 2004
- Full Text
- View/download PDF
28. Fibroblast Growth Factor Receptor 3 (FGFR3) – Analyses of the S249C mutation and protein expression in primary cervical carcinomas.
- Author
-
Dai, Haiyan, Holm, Ruth, Kristensen, Gunnar B., Abeler, Vera M., Børresen-Dale, Anne-Lise, and Helland, Åslaug
- Subjects
FIBROBLAST growth factors ,PROTEINS ,CERVICAL cancer - Abstract
Fibroblast growth factor receptor 3 (FGFR3) seems to play an inhibitory role in bone development, as activating mutations in the gene underlie disorders such as achondroplasia and thanatophoric dysplasia. Findings from multiple myeloma (MM) indicate that FGFR3 also can act as an oncogene, and mutation of codon 249 in the fibroblast growth factor receptor 3 (FGFR3) gene was recently detected in 3/12 primary cervical carcinomas. We have analysed 91 cervical carcinomas for this specific S249C mutation using amplification created restriction site methodology (ACRS), and detected no mutations. Immunohistochemistry was performed on 73 of the tumours. Reduced protein staining was seen in 43 (58.8%) samples. Six of the tumours (8.2%) revealed increased protein staining compared with normal cervical tissue. These patients had a better prognosis than those with reduced or normal levels, although not statistically significant.This report weakens the hypothesis of FGFR3 as an oncogene of importance in cervical carcinomas. [ABSTRACT FROM AUTHOR]
- Published
- 2001
- Full Text
- View/download PDF
29. Salvage Radiation for Pelvic Relapse after Surgically Treated Endometrial Cancer.
- Author
-
Lindemann, Kristina, Smogeli, Elisabeth, Småstuen, Milada Cvancarova, Bruheim, Kjersti, Trovik, Jone, Nordberg, Terje, Kristensen, Gunnar B., Werner, Henrica M. J., Nakken, Esten, and Katsaròs, Dionyssios
- Subjects
RESEARCH ,CONFIDENCE intervals ,CANCER relapse ,MEDICAL cooperation ,RETROSPECTIVE studies ,TREATMENT effectiveness ,ENDOMETRIAL tumors ,KAPLAN-Meier estimator ,DESCRIPTIVE statistics ,SALVAGE therapy ,PROPORTIONAL hazards models - Abstract
Simple Summary: This multicenter retrospective study aimed to describe the outcomes of patients with endometrial cancer after central pelvic/vaginal relapse treated with radical radiotherapy (RT). We included 139 patients with a median follow-up time of 6.66 years. Patients were treated with external beam radiotherapy to elective pelvic lymph-node regions and boost to the pelvic tumor. During follow-up, 55 (39.6%) patients developed a second relapse, the majority (75%) with disease sites outside the radiation field. Risk group at primary diagnosis and type of boost administration were independent predictors of progression-free and overall survival. Five-year overall survival for the whole cohort was 68% (95% CI: 59–75%). The majority of isolated pelvic recurrences in RT-naive women with EC can be successfully salvaged by RT but survival in high-risk patients remains suboptimal. Individualizing of adjuvant treatment in first line and better treatment alternatives at relapse are important to ultimately improve survival. (1) Background: This study evaluated the clinical outcome after salvage radiotherapy for first pelvic relapse after endometrial cancer (EC). (2) Methods: This multicenter retrospective study included EC patients with first central pelvic relapse without lymph node involvement treated with curative intent. Progression-free (PFS) and overall survival (OS) were calculated with the Kaplan–Meier method and possible predictive factors for risk of relapse and mortality were identified using the Cox model. (3) Results: We included 139 patients with median EQD2 (Equivalent Dose in 2 Gy fractions) to the clinical target volume of 70.0 Gy. During follow up of median 6.66 years, 39.6% patients developed a second relapse. Risk group classification at primary diagnosis based on histology, grading and FIGO stage and how the pelvic tumor boost was administered were independently associated with PFS and OS. Five-year OS was 68% (95% CI (59–75)) for the whole cohort. Five-year OS was 88% (95% CI (75–94)), 72% (95% CI (55–84)) and 38% (95% CI (15–60)) for the stage I low-, intermediate- and high-risk group, respectively. (4) Conclusions: The majority of central pelvic recurrences in RT-naive EC women can be successfully salvaged with radiotherapy. However, survival in patients with high-risk disease remains poor and warrants a more individualized approach to optimize outcome. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
30. Prognostic Value of the Diversity of Nuclear Chromatin Compartments in Gynaecological Carcinomas.
- Author
-
Kleppe, Andreas, Albregtsen, Fritz, Trovik, Jone, Kristensen, Gunnar B., and Danielsen, Håvard E.
- Subjects
CANCER prognosis ,CHROMOSOMES ,CONFIDENCE intervals ,STATISTICAL correlation ,DNA ,FEMALE reproductive organ tumors ,TUMOR markers ,DESCRIPTIVE statistics ,DISEASE risk factors - Abstract
Simple Summary: Chromatin organisation affects gene expression and contributes to carcinogenesis. Automatic quantification of chromatin heterogeneity can be applied to identify patients with increased risk of cancer recurrence and death in several cancer types. We aimed to investigate the prognostic role of diversity of chromatin compartments in relation to chromatin heterogeneity and as a potential supplement to pathological risk classifications in gynaecological carcinomas. To this end, we computed the entropy of both chromatin compartment sizes and optical densities within compartments. In analysis of two cohorts consisting of 1037 patients with gynaecological carcinoma, we observed a moderately strong correlation between the prognostic value of the entropies and chromatin heterogeneity. The entropies provided an objective marker, which, integrated with pathological risk classifications, might possibly contribute to the selection of high-risk stage I ovarian carcinoma patients for adjuvant chemotherapy and to preoperative identification of low-risk endometrial carcinoma patients who are candidates for less extensive surgery. Statistical texture analysis of cancer cell nuclei stained for DNA has recently been used to develop a pan-cancer prognostic marker of chromatin heterogeneity. In this study, we instead analysed chromatin organisation by automatically quantifying the diversity of chromatin compartments in cancer cell nuclei. The aim was to investigate the prognostic value of such an assessment in relation to chromatin heterogeneity and as a potential supplement to pathological risk classifications in gynaecological carcinomas. The diversity was quantified by calculating the entropy of both chromatin compartment sizes and optical densities within compartments. We analysed a median of 281 nuclei (interquartile range (IQR), 273 to 289) from 246 ovarian carcinoma patients and a median of 997 nuclei (IQR, 502 to 1452) from 791 endometrial carcinoma patients. The prognostic value of the entropies and chromatin heterogeneity was moderately strongly correlated (r ranged from 0.68 to 0.73), but the novel marker was observed to provide additional prognostic information. In multivariable analysis with clinical and pathological markers, the hazard ratio associated with the novel marker was 2.1 (95% CI, 1.3 to 3.5) in ovarian carcinoma and 2.4 (95% CI, 1.5 to 3.9) in endometrial carcinoma. Integration with pathological risk classifications gave three risk groups with distinctly different prognoses. This suggests that the novel marker of diversity of chromatin compartments might possibly contribute to the selection of high-risk stage I ovarian carcinoma patients for adjuvant chemotherapy and low-risk endometrial carcinoma patients for less extensive surgery. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
31. Deregulation of MYCN, LIN28B and LET7 in a Molecular Subtype of Aggressive High-Grade Serous Ovarian Cancers
- Author
-
Anglesio, Michael S., George, Joshy, Cowin, Prue A., House, Colin M., Sheppard, Karen E., Etemadmoghadam, Dariush, Melnyk, Nataliya, Rustgi, Anil K., Phillips, Wayne A., Johnsen, Hilde, Holm, Ruth, Kristensen, Gunnar B., Pearson, Richard B., Huntsman, David G., deFazio, Anna, Creighton, Chad J., Smyth, Gordon K., Bowtell, David D. L., Tan, Patrick, Helland, Åslaug, Johnstone, Cameron N., Birrer, Michael James, and Børresen-Dale, Anne-Lise
- Subjects
genomics ,biology ,genome expression analysis ,medicine ,obstetrics and gynecology ,gynecologic cancers ,oncology - Abstract
Molecular subtypes of serous ovarian cancer have been recently described. Using data from independent datasets including over 900 primary tumour samples, we show that deregulation of the Let-7 pathway is specifically associated with the C5 molecular subtype of serous ovarian cancer. DNA copy number and gene expression of HMGA2, alleles of Let-7, LIN28, LIN28B, MYC, MYCN, DICER1, and RNASEN were measured using microarray and quantitative reverse transcriptase PCR. Immunohistochemistry was performed on 127 samples using tissue microarrays and anti-HMGA2 antibodies. Fluorescence in situ hybridisation of bacterial artificial chromosomes hybridized to 239 ovarian tumours was used to measure translocation at the LIN28B locus. Short interfering RNA knockdown in ovarian cell lines was used to test the functionality of associations observed. Four molecular subtypes (C1, C2, C4, C5) of high-grade serous ovarian cancers were robustly represented in each dataset and showed similar pattern of patient survival. We found highly specific activation of a pathway involving MYCN, LIN28B, Let-7 and HMGA2 in the C5 molecular subtype defined by MYCN amplification and over-expression, over-expression of MYCN targets including the Let-7 repressor LIN28B, loss of Let-7 expression and HMGA2 amplification and over-expression. DICER1, a known Let-7 target, and RNASEN were over-expressed in C5 tumours. We saw no evidence of translocation at the LIN28B locus in C5 tumours. The reported interaction between LIN28B and Let-7 was recapitulated by siRNA knockdown in ovarian cancer cell lines. Our results associate deregulation of MYCN and downstream targets, including Let-7 and oncofetal genes, with serous ovarian cancer. We define for the first time how elements of an oncogenic pathway, involving multiple genes that contribute to stem cell renewal, is specifically altered in a molecular subtype of serous ovarian cancer. By defining the drivers of a molecular subtype of serous ovarian cancers we provide a novel strategy for targeted therapeutic intervention.
- Published
- 2011
- Full Text
- View/download PDF
32. Effect of the codon 72 polymorphism (c.215G>C, p.Arg72Pro) in combination with somatic sequence variants in the TP53 gene on survival in patients with advanced ovarian carcinoma.
- Author
-
Wang, Yun, Kringen, Pedro, Kristensen, Gunnar B., Holm, Ruth, Baekelandt, Mark M.O., Olivier, Magali, Skomedal, Hanne, Hainaut, Pierre, Tropé, Claes G., Abeler, Vera M., Nesland, Jahn M., Børresen-Dale, Anne-Lise, and Helland, Åslaug
- Published
- 2006
- Full Text
- View/download PDF
33. PIK3CA mutations in advanced ovarian carcinomas.
- Author
-
Wang, Yun, Helland, Åslaug, Holm, Ruth, Kristensen, Gunnar B., and Børresen-Dale, Anne-Lise
- Abstract
PIK3CA belongs to the phosphatidylinositol 3-kinases (PI3Ks) family, which play an important role in proliferation, adherence, transformation and cell survival through the PI3K/AKT signaling pathway. Somatic activating mutations of this gene have recently been detected in several types of cancers. In the present study, 109 advanced ovarian carcinomas were analyzed for PIK3CA mutations in exon 9 and exon 20 by direct sequencing. Activating missense mutations were observed in 4 of the 109 tumors in addition to one variant leading no change of the PIK3CA protein. Two of the cases with mutations were mucinous and clear cell tumors, suggesting that PIK3CA mutations are more common in these rare histological types. © 2005 Wiley-Liss, Inc. [ABSTRACT FROM AUTHOR]
- Published
- 2005
- Full Text
- View/download PDF
34. Hypoxia-Induced Gene Expression in Chemoradioresistant Cervical Cancer Revealed by Dynamic Contrast-Enhanced MRI.
- Author
-
Halle, Cathinka, Andersen, Erlend, Lando, Malin, Aarnes, Eva-Katrine, Hasvold, Grete, Holden, Marit, Syljuåsen, Randi G., Sundfør, Kolbein, Kristensen, Gunnar B., Holm, Ruth, Malinen, Eirik, and Heidi Lyng
- Subjects
- *
MAGNETIC resonance imaging of cancer , *CERVICAL cancer , *CANCER treatment , *CANCER genetics , *HYPOXEMIA , *CANCER prognosis - Abstract
Knowledge of the molecular background of functional magnetic resonance (MR) images is required to fully exploit their potential in cancer management. We explored the prognostic impact of dynamic contrast-enhanced MR imaging (DCE-MRI) parameters in cervical cancer combined with global gene expression data to reveal their underlying molecular phenotype and construct a representative gene signature for the relevant parameter. On the basis of 78 patients with cervical cancer subjected to curative chemoradiotherapy, we identified the prognostic DCE-MRI parameter ABrix by pharmacokinetic analysis of pretreatment images based on the Brix model, in which tumors with low ABrix appeared to be most aggressive. Gene set analysis of 46 tumors with pairwise DCE-MRI and gene expression data showed a significant correlation between ABrix and the hypoxia gene sets, whereas gene sets related to other tumor phenotypes were not significant. Hypoxia gene sets specific for cervical cancer created in cell culture experiments, including both targets of the hypoxia inducible factor (HIF1α) and the unfolded protein response, were the most significant. In the remaining 32 tumors, low ABrix was associated with upregulation of HIF1α protein expression, as assessed by immunohistochemistry, consistent with increased hypoxia. On the basis of the hypoxia gene sets, a signature of 31 genes that were upregulated in tumors with low ABrix was constructed. This DCE-MRI hypoxia gene signature showed prognostic impact in an independent validation cohort of 109 patients. Our findings reveal the molecular basis of an aggressive hypoxic phenotype and suggest the use of DCE-MRI to noninvasively identify patients with hypoxia-related chemoradioresistance. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
35. MRI Distinguishes Tumor Hypoxia Levels of Different Prognostic and Biological Significance in Cervical Cancer.
- Author
-
Hillestad T, Hompland T, Fjeldbo CS, Skingen VE, Salberg UB, Aarnes EK, Nilsen A, Lund KV, Evensen TS, Kristensen GB, Stokke T, and Lyng H
- Subjects
- Algorithms, Animals, Cell Line, Tumor, Chemoradiotherapy, Contrast Media, Epithelial-Mesenchymal Transition genetics, Female, G2 Phase Cell Cycle Checkpoints genetics, Gene Expression Profiling methods, HeLa Cells, Humans, Hypoxia-Inducible Factor 1, alpha Subunit metabolism, M Phase Cell Cycle Checkpoints genetics, Mice, Mice, Nude, Neoplasm Transplantation, Nitroimidazoles, Oxidative Phosphorylation, Oxygen Consumption, Prognosis, Treatment Outcome, Uterine Cervical Neoplasms diagnostic imaging, Uterine Cervical Neoplasms genetics, Uterine Cervical Neoplasms therapy, Magnetic Resonance Imaging methods, Tumor Hypoxia genetics, Uterine Cervical Neoplasms metabolism
- Abstract
Tumor hypoxia levels range from mild to severe and have different biological and therapeutical consequences but are not easily assessable in patients. Here we present a method based on diagnostic dynamic contrast enhanced (DCE) MRI that reflects a continuous range of hypoxia levels in patients with tumors of cervical cancer. Hypoxia images were generated using an established approach based on pixel-wise combination of DCE-MRI parameters ν
e and Ktrans , representing oxygen consumption and supply, respectively. Using two tumor models, an algorithm to retrieve surrogate measures of hypoxia levels from the images was developed and validated by comparing the MRI-defined levels with hypoxia levels reflected in pimonidazole-stained histologic sections. An additional indicator of hypoxia levels in patient tumors was established on the basis of expression of nine hypoxia-responsive genes; a strong correlation was found between these indicator values and MRI-defined hypoxia levels in 63 patients. Chemoradiotherapy outcome of 74 patients was most strongly predicted by moderate hypoxia levels, whereas more severe or milder levels were less predictive. By combining gene expression profiles and MRI-defined hypoxia levels in cancer hallmark analysis, we identified a distribution of levels associated with each hallmark; oxidative phosphorylation and G2 -M checkpoint were associated with moderate hypoxia, epithelial-to-mesenchymal transition, and inflammatory responses with significantly more severe levels. At the mildest levels, IFN response hallmarks together with HIF1A protein expression by IHC appeared significant. Thus, our method visualizes the distribution of hypoxia levels within patient tumors and has potential to distinguish levels of different prognostic and biological significance. SIGNIFICANCE: These findings present an approach to image a continuous range of hypoxia levels in tumors and demonstrate the combination of imaging with molecular data to better understand the biology behind these different levels., (©2020 American Association for Cancer Research.)- Published
- 2020
- Full Text
- View/download PDF
36. Combining imaging- and gene-based hypoxia biomarkers in cervical cancer improves prediction of chemoradiotherapy failure independent of intratumour heterogeneity.
- Author
-
Fjeldbo CS, Hompland T, Hillestad T, Aarnes EK, Günther CC, Kristensen GB, Malinen E, and Lyng H
- Subjects
- Adult, Aged, Aged, 80 and over, Chemoradiotherapy adverse effects, Diagnostic Imaging, Female, Gene Expression Profiling, Humans, Middle Aged, Norway epidemiology, Prognosis, Progression-Free Survival, Treatment Outcome, Tumor Hypoxia drug effects, Tumor Hypoxia radiation effects, Uterine Cervical Neoplasms diagnostic imaging, Uterine Cervical Neoplasms genetics, Biomarkers, Tumor genetics, Neoplasm Proteins genetics, Uterine Cervical Neoplasms drug therapy, Uterine Cervical Neoplasms radiotherapy
- Abstract
Background: Emerging biomarkers from medical imaging or molecular characterization of tumour biopsies open up for combining the two and exploiting their synergy in treatment planning of cancer patients. We generated a paired data set of imaging- and gene-based hypoxia biomarkers in cervical cancer, appraised the influence of intratumour heterogeneity in patient classification, and investigated the benefit of combining the methodologies in prediction of chemoradiotherapy failure., Methods: Hypoxic fraction from dynamic contrast enhanced (DCE)-MR images and an expression signature of six hypoxia-responsive genes were assessed as imaging- and gene-based biomarker, respectively in 118 patients., Findings: Dichotomous biomarker cutoff to yield similar hypoxia status by imaging and genes was defined in 41 patients, and the association was validated in the remaining 77 patients. The two biomarkers classified 75% of 118 patients with the same hypoxia status, and inconsistent classification was not related to imaging-defined intratumour heterogeneity in hypoxia. Gene-based hypoxia was independent on tumour cell fraction in the biopsies and showed minor heterogeneity across multiple samples in 9 tumours. Combining imaging- and gene-based classification gave a significantly better prediction of PFS than one biomarker alone. A combined dichotomous biomarker optimized in 77 patients showed a large separation in PFS between more and less hypoxic tumours, and separated the remaining 41 patients with different PFS. The combined biomarker showed prognostic value together with tumour stage in multivariate analysis., Interpretation: Combining imaging- and gene-based biomarkers may enable more precise and informative assessment of hypoxia-related chemoradiotherapy resistance in cervical cancer., Funding: Norwegian Cancer Society, South-Eastern Norway Regional Health Authority, and Norwegian Research Council., Competing Interests: Declaration of Competing Interest HL is registered as inventor of a patent application covering the clinical use of the hypoxia gene signature (WO2013/124,738)., (Copyright © 2020 The Authors. Published by Elsevier B.V. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
37. Integrated Molecular Analysis of Undifferentiated Uterine Sarcomas Reveals Clinically Relevant Molecular Subtypes.
- Author
-
Binzer-Panchal A, Hardell E, Viklund B, Ghaderi M, Bosse T, Nucci MR, Lee CH, Hollfelder N, Corcoran P, Gonzalez-Molina J, Moyano-Galceran L, Bell DA, Schoolmeester JK, Måsbäck A, Kristensen GB, Davidson B, Lehti K, Isaksson A, and Carlson JW
- Subjects
- Chromosome Aberrations, Computational Biology methods, DNA Copy Number Variations, Female, Gene Expression Profiling, Gene Ontology, Humans, Image Processing, Computer-Assisted, Immunohistochemistry, Kaplan-Meier Estimate, Molecular Diagnostic Techniques, Neoplasm Grading, Prognosis, Proportional Hazards Models, Proteomics methods, Sarcoma mortality, Uterine Neoplasms mortality, Biomarkers, Tumor, Sarcoma diagnosis, Sarcoma etiology, Uterine Neoplasms diagnosis, Uterine Neoplasms etiology
- Abstract
Purpose: Undifferentiated uterine sarcomas (UUS) are rare, extremely deadly, sarcomas with no effective treatment. The goal of this study was to identify novel intrinsic molecular UUS subtypes using integrated clinical, histopathologic, and molecular evaluation of a large, fully annotated, patient cohort., Experimental Design: Fifty cases of UUS with full clinicopathologic annotation were analyzed for gene expression ( n = 50), copy-number variation (CNV, n = 40), cell morphometry ( n = 39), and protein expression ( n = 22). Gene ontology and network enrichment analysis were used to relate over- and underexpressed genes to pathways and further to clinicopathologic and phenotypic findings., Results: Gene expression identified four distinct groups of tumors, which varied in their clinicopathologic parameters. Gene ontology analysis revealed differential activation of pathways related to genital tract development, extracellular matrix (ECM), muscle function, and proliferation. A multivariable, adjusted Cox proportional hazard model demonstrated that RNA group, mitotic index, and hormone receptor expression influence patient overall survival (OS). CNV arrays revealed characteristic chromosomal changes for each group. Morphometry demonstrated that the ECM group, the most aggressive, exhibited a decreased cell density and increased nuclear area. A cell density cutoff of 4,300 tumor cells per mm
2 could separate ECM tumors from the remaining cases with a sensitivity of 83% and a specificity of 94%. IHC staining of MMP-14, Collagens 1 and 6, and Fibronectin proteins revealed differential expression of these ECM-related proteins, identifying potential new biomarkers for this aggressive sarcoma subgroup., Conclusions: Molecular evaluation of UUS provides novel insights into the biology, prognosis, phenotype, and possible treatment of these tumors., (©2019 American Association for Cancer Research.)- Published
- 2019
- Full Text
- View/download PDF
38. Integrative Analysis of DCE-MRI and Gene Expression Profiles in Construction of a Gene Classifier for Assessment of Hypoxia-Related Risk of Chemoradiotherapy Failure in Cervical Cancer.
- Author
-
Fjeldbo CS, Julin CH, Lando M, Forsberg MF, Aarnes EK, Alsner J, Kristensen GB, Malinen E, and Lyng H
- Subjects
- Adult, Aged, Aged, 80 and over, Chemoradiotherapy, Cohort Studies, Combined Modality Therapy, Female, Gene Expression Profiling, Gene Expression Regulation, Neoplastic, Humans, Hypoxia metabolism, Image Enhancement, Middle Aged, Neoplasm Metastasis, Neoplasm Staging, Prognosis, Proportional Hazards Models, Treatment Failure, Treatment Outcome, Uterine Cervical Neoplasms mortality, Uterine Cervical Neoplasms therapy, Young Adult, Hypoxia genetics, Magnetic Resonance Imaging methods, Transcriptome, Uterine Cervical Neoplasms diagnosis, Uterine Cervical Neoplasms genetics
- Abstract
Purpose: A 31-gene expression signature reflected in dynamic contrast enhanced (DCE)-MR images and correlated with hypoxia-related aggressiveness in cervical cancer was identified in previous work. We here aimed to construct a dichotomous classifier with key signature genes and a predefined classification threshold that separated cervical cancer patients into a more and less hypoxic group with different outcome to chemoradiotherapy., Experimental Design: A training cohort of 42 patients and two independent cohorts of 108 and 131 patients were included. Gene expression data were generated from tumor biopsies by two Illumina array generations (WG-6, HT-12). Technical transfer of the classifier to a reverse transcription quantitative PCR (RT-qPCR) platform was performed for 74 patients. The amplitude ABrix in the Brix pharmacokinetic model was extracted from DCE-MR images of 64 patients and used as an indicator of hypoxia., Results: Classifier candidates were constructed by integrative analysis of ABrix and gene expression profiles in the training cohort and evaluated by a leave-one-out cross-validation approach. On the basis of their ability to separate patients correctly according to hypoxia status, a 6-gene classifier was identified. The classifier separated the patients into two groups with different progression-free survival probability. The robustness of the classifier was demonstrated by successful validation of hypoxia association and prognostic value across cohorts, array generations, and assay platforms. The prognostic value was independent of existing clinical markers, regardless of clinical endpoints., Conclusions: A robust DCE-MRI-associated gene classifier has been constructed that may be used to achieve an early indication of patients' risk of hypoxia-related chemoradiotherapy failure. Clin Cancer Res; 22(16); 4067-76. ©2016 AACR., (©2016 American Association for Cancer Research.)
- Published
- 2016
- Full Text
- View/download PDF
39. The prognostic value of adaptive nuclear texture features from patient gray level entropy matrices in early stage ovarian cancer.
- Author
-
Nielsen B, Albregtsen F, Kildal W, Abeler VM, Kristensen GB, and Danielsen HE
- Subjects
- Algorithms, Female, Follow-Up Studies, Humans, Image Processing, Computer-Assisted methods, Kaplan-Meier Estimate, Microscopy methods, Multivariate Analysis, Neoplasm Staging, Prognosis, Retrospective Studies, Rosaniline Dyes, Cell Nucleus pathology, Entropy, Ovarian Neoplasms diagnosis, Ovary pathology
- Abstract
Background: Nuclear texture analysis gives information about the spatial arrangement of the pixel gray levels in a digitized microscopic nuclear image, providing texture features that may be used as quantitative tools for prognosis of human cancer. The aim of the study was to evaluate the prognostic value of adaptive nuclear texture features in early stage ovarian cancer., Methods: 246 cases of early stage ovarian cancer were included in the analysis. Isolated nuclei (monolayers) were prepared from 50 μm tissue sections and stained with Feulgen-Schiff. Local gray level entropy was measured within small windows of each nuclear image and stored in gray level entropy matrices. A compact set of adaptive features was computed from these matrices., Results: Univariate Kaplan-Meier analysis showed significantly better relapse-free survival (p < 0.001) for patients with low adaptive feature values compared to patients with high adaptive feature values. The 10-year relapse-free survival was about 78% for patients with low feature values and about 52% for patients with high feature values. Adaptive features were found to be of independent prognostic significance for relapse-free survival in a multivariate analysis., Conclusion: Adaptive nuclear texture features from entropy matrices contain prognostic information and are of independent prognostic significance for relapse-free survival in early stage ovarian cancer.
- Published
- 2012
- Full Text
- View/download PDF
40. Membranous expression of ectodomain isoforms of the epidermal growth factor receptor predicts outcome after chemoradiotherapy of lymph node-negative cervical cancer.
- Author
-
Halle C, Lando M, Svendsrud DH, Clancy T, Holden M, Sundfør K, Kristensen GB, Holm R, and Lyng H
- Subjects
- Adult, Aged, Blotting, Western, Carcinoma, Squamous Cell genetics, Cell Membrane metabolism, Chemoradiotherapy, Cohort Studies, ErbB Receptors genetics, Female, Gene Expression Profiling, Gene Expression Regulation, Neoplastic, Gene Regulatory Networks, Humans, Immunohistochemistry, Kaplan-Meier Estimate, Lymph Nodes metabolism, Lymph Nodes pathology, Middle Aged, Phosphorylation, Prognosis, Protein Isoforms genetics, Protein Isoforms metabolism, Reverse Transcriptase Polymerase Chain Reaction, Treatment Outcome, Uterine Cervical Neoplasms genetics, Carcinoma, Squamous Cell metabolism, Carcinoma, Squamous Cell therapy, ErbB Receptors metabolism, Uterine Cervical Neoplasms metabolism, Uterine Cervical Neoplasms therapy
- Abstract
Purpose: We compared the prognostic significance of ectodomain isoforms of the epidermal growth factor receptor (EGFR), which lack the tyrosine kinase (TK) domain, with that of the full-length receptor and its autophosphorylation status in cervical cancers treated with conventional chemoradiotherapy., Experimental Design: Expression of EGFR isoforms was assessed by immunohistochemistry in a prospectively collected cohort of 178 patients with squamous cell cervical carcinoma, and their detection was confirmed with Western blotting and reverse transcriptase PCR. A proximity ligation immunohistochemistry assay was used to assess EGFR-specific autophosphorylation. Pathways associated with the expression of ectodomain isoforms were studied by gene expression analysis with Illumina beadarrays in 110 patients and validated in an independent cohort of 41 patients., Results: Membranous expression of ectodomain isoforms alone, without the coexpression of the full-length receptor, showed correlations to poor clinical outcome that were highly significant for lymph node-negative patients (locoregional control, P = 0.0002; progression-free survival, P < 0.0001; disease-specific survival, P = 0.005 in the log-rank test) and independent of clinical variables. The ectodomain isoforms were primarily 60-kD products of alternative EGFR transcripts. Their membranous expression correlated with transcriptional regulation of oncogenic pathways including activation of MYC and MAX, which was significantly associated with poor outcome. This aggressive phenotype of ectodomain EGFR expressing tumors was confirmed in the independent cohort. Neither total nor full-length EGFR protein level, or autophosphorylation status, showed prognostic significance., Conclusion: Membranous expression of ectodomain EGFR isoforms, and not TK activation, predicts poor outcome after chemoradiotherapy for patients with lymph node-negative cervical cancer., (©2011 AACR.)
- Published
- 2011
- Full Text
- View/download PDF
41. Expressions of EphA2 and EphrinA-1 in early squamous cell cervical carcinomas and their relation to prognosis.
- Author
-
Holm R, de Putte GV, Suo Z, Lie AK, and Kristensen GB
- Subjects
- Adult, Carcinoma, Squamous Cell mortality, Disease-Free Survival, Female, Humans, Immunohistochemistry methods, Middle Aged, Models, Biological, Prognosis, Retrospective Studies, Treatment Outcome, Uterine Cervical Neoplasms mortality, Carcinoma, Squamous Cell metabolism, Ephrin-A1 biosynthesis, Ephrin-A2 biosynthesis, Uterine Cervical Neoplasms metabolism
- Abstract
By using immunohistochemistry we investigated the expression of EphA2 and EphrinA-1 in 217 early squamous cell cervical carcinomas and examine their prognostic relevance. For EphA2 expression, 21 tumors (10%) showed negative, 108 (50%) weak positive, 69 (32%) moderate positive and 19 (9%) strong positive, whereas for EphrinA-1 expression, 33 tumors (15%) showed negative, 91 (42%) weak positive, 67 (31%) moderate positive and 26 (12%) strong positive. In univariate analysis high expression (strong staining) of EphrinA-1 was associated with poor disease-free (P = 0.033) and disease-specific (P = 0.039) survival. However, in the multivariate analyses neither EphrinA-1 nor EphA2 was significantly associated to survival. The increased levels of EphA2 and EphrinA-1 in a relative high number of early stage squamous cell carcinomas suggested that these two proteins may play an important role in the development of a subset of early cervical cancers. However, EphA2 and EphrinA-1 were not independently associated with clinical outcome.
- Published
- 2008
- Full Text
- View/download PDF
42. Human papillomavirus DNA and e6/e7 mRNA status in relation to survival of patients treated for cervical squamous cell carcinoma.
- Author
-
Holm R, Kraus I, Skomedal H, Langerød A, Kristensen GB, and Lyng H
- Abstract
The prognostic significance of human papillomavirus (HPV) DNA and E6/E7 mRNA, the presence of specific types, and the physical state of HPV DNA, were studied in 202 cervical squamous cell carcinomas. Absence or non-detectable levels of high-risk (types 16, 18, 31, 33, 35, 45, 52 and 58) E6/E7 mRNA, using the real-time nucleic acid sequence based amplification (NASBA) assay, and absence of HPV high-risk/HPV 6, 26, 66, 69, 73 (all methods collectively) were associated with poor overall survival in univariate analysis (P = 0.04 and P = 0.03, respectively) and had independent prognostic value in multivariate analysis (P = 0.01 and P = 0.03, respectively) including FIGO stage and age. Based on the individual results of type-specific PCR and in situ hybridization (ISH), the presence of HPV DNA was not found to be a prognostic factor. Likewise, concerning the presence of specific HPV types and the HPV integration status (determined by ISH), no prognostic significance was found. Mutation analyses of the TP53 gene revealed mutations in 3 of the 6 HPV negative samples (50%).
- Published
- 2008
- Full Text
- View/download PDF
43. GeneCount: genome-wide calculation of absolute tumor DNA copy numbers from array comparative genomic hybridization data.
- Author
-
Lyng H, Lando M, Brøvig RS, Svendsrud DH, Johansen M, Galteland E, Brustugun OT, Meza-Zepeda LA, Myklebost O, Kristensen GB, Hovig E, and Stokke T
- Subjects
- Carcinoma, Squamous Cell genetics, Female, Humans, Lymphoma, Non-Hodgkin genetics, Translocation, Genetic, Uterine Cervical Neoplasms genetics, DNA, Neoplasm genetics, Gene Dosage, Nucleic Acid Hybridization methods
- Abstract
Absolute tumor DNA copy numbers can currently be achieved only on a single gene basis by using fluorescence in situ hybridization (FISH). We present GeneCount, a method for genome-wide calculation of absolute copy numbers from clinical array comparative genomic hybridization data. The tumor cell fraction is reliably estimated in the model. Data consistent with FISH results are achieved. We demonstrate significant improvements over existing methods for exploring gene dosages and intratumor copy number heterogeneity in cancers.
- Published
- 2008
- Full Text
- View/download PDF
44. Metabolic mapping by use of high-resolution magic angle spinning 1H MR spectroscopy for assessment of apoptosis in cervical carcinomas.
- Author
-
Lyng H, Sitter B, Bathen TF, Jensen LR, Sundfør K, Kristensen GB, and Gribbestad IS
- Subjects
- Biopsy, Needle, Female, Humans, Probability, Sensitivity and Specificity, Apoptosis, Carcinoma, Squamous Cell pathology, Magnetic Resonance Spectroscopy methods, Uterine Cervical Neoplasms pathology
- Abstract
Background: High-resolution magic angle proton magnetic resonance spectroscopy (HR 1H MAS MRS) provides a broad metabolic mapping of intact tumor samples and allows for microscopy investigations of the samples after spectra acquisition. Experimental studies have suggested that the method can be used for detection of apoptosis, but this has not been investigated in a clinical setting so far. We have explored this hypothesis in cervical cancers by searching for metabolites associated with apoptosis that were not influenced by other histopathological parameters like tumor load and tumor cell density., Methods: Biopsies (n = 44) taken before and during radiotherapy in 23 patients were subjected to HR MAS MRS. A standard pulse-acquire spectrum provided information about lipids, and a spin-echo spectrum enabled detection of non-lipid metabolites in the lipid region of the spectra. Apoptotic cell density, tumor cell fraction, and tumor cell density were determined by histopathological analysis after spectra acquisition., Results: The apoptotic cell density correlated with the standard pulse-acquire spectra (p < 0.001), but not with the spin-echo spectra, showing that the lipid metabolites were most important. The combined information of all lipids contributed to the correlation, with a major contribution from the ratio of fatty acid -CH2 to CH3 (p = 0.02). In contrast, the spin-echo spectra contained the main information on tumor cell fraction and tumor cell density (p < 0.001), for which cholines, creatine, taurine, glucose, and lactate were most important. Significant correlations were found between tumor cell fraction and glucose concentration (p = 0.001) and between tumor cell density and glycerophosphocholine (GPC) concentration (p = 0.024) and ratio of GPC to choline (p < 0.001)., Conclusion: Our findings indicate that the apoptotic activity of cervical cancers can be assessed from the lipid metabolites in HR MAS MR spectra and that the HR MAS data may reveal novel information on the metabolic changes characteristic of apoptosis. These changes differed from those associated with tumor load and tumor cell density, suggesting an application of the method to explore the role of apoptosis in the course of the disease.
- Published
- 2007
- Full Text
- View/download PDF
45. Presence of E6 and E7 mRNA from human papillomavirus types 16, 18, 31, 33, and 45 in the majority of cervical carcinomas.
- Author
-
Kraus I, Molden T, Holm R, Lie AK, Karlsen F, Kristensen GB, and Skomedal H
- Subjects
- Carcinoma, Squamous Cell pathology, Cell Line, DNA, Viral analysis, Female, HeLa Cells, Humans, Oncogene Proteins, Viral biosynthesis, Papillomaviridae classification, Papillomaviridae genetics, RNA, Viral analysis, Uterine Cervical Neoplasms pathology, Vaginal Smears, Uterine Cervical Dysplasia pathology, Carcinoma, Squamous Cell virology, Oncogene Proteins, Viral genetics, Papillomaviridae isolation & purification, Papillomavirus Infections diagnosis, RNA, Messenger analysis, Uterine Cervical Neoplasms virology, Uterine Cervical Dysplasia virology
- Abstract
The oncogenic potential of the human papillomavirus (HPV) early genes E6 and E7 is well established and a source of interest with regard to HPV testing for cervical carcinoma. Here we present a study performed with 204 histologically confirmed invasive cervical squamous cell carcinomas (SCCs) in which we evaluated the HPV E6 and E7 mRNA detection assay PreTect HPV-Proofer for detection of high-risk HPV types 16, 18, 31, 33, and 45. For further evaluation, detection of E6 and E7 mRNA from HPV types 35, 52, and 58 by real-time multiplex nucleic acid sequence-based amplification was also included. For comparison and to assess the overall prevalence of various HPV types, samples were also tested for HPV DNA by both consensus and type-specific PCR, reverse line blotting, sequencing, and in situ hybridization. The overall prevalence of HPV was 97%. HPV E6 and E7 transcripts were detected in 188 of 204 (92%) biopsy specimens, of which 181 contained one of the following HPV types: 16, 18, 31, 33, or 45. Consensus PCR and type-specific PCR detected HPV in 187 of 204 and 188 of 204 (92%) specimens, respectively. In conclusion, this study verifies the presence of HPV E6 and E7 mRNA in SCCs and demonstrates that HPV infections among Norwegian women with SCCs are limited mainly to the five high-risk types, 16, 18, 31, 33, and 45. This, together with the fact that PreTect HPV-Proofer detects the HPV oncogenic transcripts, suggests that the assay is a valuable approach in the field of HPV detection in cervical carcinoma.
- Published
- 2006
- Full Text
- View/download PDF
46. Proteomic analysis of malignant ovarian cancer effusions as a tool for biologic and prognostic profiling.
- Author
-
Davidson B, Espina V, Steinberg SM, Flørenes VA, Liotta LA, Kristensen GB, Tropé CG, Berner A, and Kohn EC
- Subjects
- Apoptosis physiology, Ascitic Fluid metabolism, Cell Proliferation, Cell Survival physiology, Cohort Studies, Disease Progression, Female, Humans, Ovarian Neoplasms metabolism, Pleural Effusion, Malignant metabolism, Prognosis, Retrospective Studies, Signal Transduction physiology, Survival Rate, Ascitic Fluid chemistry, Ovarian Neoplasms diagnosis, Pleural Effusion, Malignant chemistry, Proteomics
- Abstract
Purpose: Malignant epithelial ovarian cancer effusions are important in disease dissemination and clinical outcome. The identification of biochemical events active in effusions may improve our identification and application of targeted therapeutics., Experimental Design: Archival effusion samples for which outcome information was known were studied. Clinical variables were comparable between these groups. Two cohorts of patients with malignant effusion were assessed: those with effusion at presentation (Tap1) or at first recurrence (Tap2). Expression and activated fraction of selected signaling proteins were quantitated on serial protein microarrays using validated antibodies. Proteomic results and clinical variables were analyzed by univariate analysis followed by Cox proportional hazards model analysis., Results: Malignant effusions (>80% malignant cells) were distinguished from benign effusions by higher expression of AKT, activated extracellular signal-regulated kinase, activated (P < or = 0.001) and total cAMP-responsive element binding protein (P = 0.01), and JNK (P = 0.03). Malignant pleural effusions could not be differentiated from ascites by signaling profiles. Both had signal expression clusters for survival, proliferation and metastasis, and injury pathways. Cox proportional hazards model analysis revealed high p38 and pEGFR/EGFR ratio as jointly associated with poor survival in Tap1 cases (both P < or = 0.002). Phospho-JNK quantity was associated with worse outcome in Tap2 patients (P = 0.004), when taking other factors into consideration., Conclusions: Proliferation, survival, and apoptosis signaling dysregulation can be identified in ovarian cancer effusion samples. Biochemical characterization of clinical effusions may provide either predictive and/or correlative information on patient outcome from which to further understand the mechanisms of effusion development and target clinical intervention.
- Published
- 2006
- Full Text
- View/download PDF
47. Apolipoprotein E is required for cell proliferation and survival in ovarian cancer.
- Author
-
Chen YC, Pohl G, Wang TL, Morin PJ, Risberg B, Kristensen GB, Yu A, Davidson B, and Shih IeM
- Subjects
- Apolipoproteins E genetics, Cell Cycle, Female, Gene Deletion, Gene Expression Regulation, Humans, Mitosis, Ovarian Neoplasms genetics, Ovarian Neoplasms mortality, RNA, Small Interfering genetics, Survival Analysis, Apolipoproteins E physiology, Cell Division physiology, Cell Survival physiology, Ovarian Neoplasms pathology
- Abstract
Apolipoprotein E (ApoE) has been recently identified as a potential tumor-associated marker in ovarian cancer by serial analysis of gene expression. ApoE has long been known to play a key role in lipid transport, and its specific isoforms may participate in atherosclerogenesis. However, its role in human cancer is not known. In this study, apoE expression was frequently detected in ovarian serous carcinomas, the most common and lethal type of ovarian cancer. It was not detected in serous borderline tumors and normal ovarian surface epithelium. Inhibition of apoE expression using an apoE-specific siRNA led to G(2) cell cycle arrest and apoptosis in an apoE-expressing ovarian cancer cell line, OVCAR3, but not in apoE-negative cell lines. Furthermore, the phenotype of apoE siRNA-treated OVCAR3 cells was reversed by expressing engineered mutant apoE with introduced silent mutations in the siRNA target sequence. Expression of apoE in nuclei was significantly associated with a better survival in patients who presented peritoneal effusion at the time of diagnosis (5-year follow-up, P = 0.004). This study suggests a new role of apoE in cancer as apoE expression is important for the proliferation and survival in apoE-expressing ovarian cancer cells.
- Published
- 2005
48. Gene expression patterns in ovarian carcinomas.
- Author
-
Schaner ME, Ross DT, Ciaravino G, Sorlie T, Troyanskaya O, Diehn M, Wang YC, Duran GE, Sikic TL, Caldeira S, Skomedal H, Tu IP, Hernandez-Boussard T, Johnson SW, O'Dwyer PJ, Fero MJ, Kristensen GB, Borresen-Dale AL, Hastie T, Tibshirani R, van de Rijn M, Teng NN, Longacre TA, Botstein D, Brown PO, and Sikic BI
- Subjects
- Adenocarcinoma metabolism, Adenocarcinoma, Clear Cell metabolism, Breast Neoplasms metabolism, Carcinoma, Papillary metabolism, Cation Transport Proteins genetics, Cation Transport Proteins metabolism, DNA-Binding Proteins genetics, DNA-Binding Proteins metabolism, Ephrin-B1 genetics, Ephrin-B1 metabolism, Female, GATA3 Transcription Factor, GPI-Linked Proteins, Humans, Immunohistochemistry, Membrane Glycoproteins genetics, Membrane Glycoproteins metabolism, Mesothelin, Neoplasm Proteins genetics, Neoplasm Proteins metabolism, Oligonucleotide Array Sequence Analysis, Ovarian Neoplasms metabolism, PAX8 Transcription Factor, Paired Box Transcription Factors, Receptors, Estrogen genetics, Receptors, Estrogen metabolism, Regulatory Factor X Transcription Factors, Trans-Activators genetics, Trans-Activators metabolism, Transcription Factors genetics, Transcription Factors metabolism, Tumor Cells, Cultured, Adenocarcinoma genetics, Adenocarcinoma, Clear Cell genetics, Breast Neoplasms genetics, Carcinoma, Papillary genetics, Nuclear Proteins, Ovarian Neoplasms genetics
- Abstract
We used DNA microarrays to characterize the global gene expression patterns in surface epithelial cancers of the ovary. We identified groups of genes that distinguished the clear cell subtype from other ovarian carcinomas, grade I and II from grade III serous papillary carcinomas, and ovarian from breast carcinomas. Six clear cell carcinomas were distinguished from 36 other ovarian carcinomas (predominantly serous papillary) based on their gene expression patterns. The differences may yield insights into the worse prognosis and therapeutic resistance associated with clear cell carcinomas. A comparison of the gene expression patterns in the ovarian cancers to published data of gene expression in breast cancers revealed a large number of differentially expressed genes. We identified a group of 62 genes that correctly classified all 125 breast and ovarian cancer specimens. Among the best discriminators more highly expressed in the ovarian carcinomas were PAX8 (paired box gene 8), mesothelin, and ephrin-B1 (EFNB1). Although estrogen receptor was expressed in both the ovarian and breast cancers, genes that are coregulated with the estrogen receptor in breast cancers, including GATA-3, LIV-1, and X-box binding protein 1, did not show a similar pattern of coexpression in the ovarian cancers.
- Published
- 2003
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.